AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease

Author's Avatar
Mar 22, 2023

AbCellera (Nasdaq: ABCL) and RQ+Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV). The partnership aims to provide long-lasting infectious diseases medicines to high-risk patients by bringing together RQ Bio’s expertise in infectious diseases and viral evolution with AbCellera’s discovery engine for finding rare, highly potent antibodies.